Association Between Changes of GFAP After Surgery and Postoperative Delayed Cognitive Recovery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Sergey Kamnev, M.D.
- Phone Number: +0079055918462
- Email: korium1605@gmail.com
Study Locations
-
-
-
Moscow, Russian Federation, 111123
- Moscow Clinical Scientific Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with different diseases, who require prolonged laparoscopy or open surgery
- Age more than 60
- ASA I-III
- Informed consent to participate in the study
Exclusion Criteria:
- ASA IV-V
- Severe neurodegenerative or psychological diseases
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Delayed Neurocognitive decline
Patients in whom there is Delayed Neurocognitive Recovery (DNR) after surgery, based on neuropsychological tests or clinically.
DNR is defined as follow: 1)decrease of scores of neuropsychological test scores for more than 1 standard deviation (SD) of these tests; 2)clinically - inability of patient to perform test after surgery because of neurocognitive impairment.
|
3 samples of serum are drawn from patients.
The 1st Sample of patient serum is drawn before induction into anesthesia.
The 2nd is drawn 24 hours after the 1st one.
The 3rd sample is drawn on 3 or 4 postoperative day.
All samples collected and preserved in the same temperature as required for ELISA.
|
|
Normal postop neurocognitive function
Patients in whom there is no clinical signs of DNR, defined as in previous group.
|
3 samples of serum are drawn from patients.
The 1st Sample of patient serum is drawn before induction into anesthesia.
The 2nd is drawn 24 hours after the 1st one.
The 3rd sample is drawn on 3 or 4 postoperative day.
All samples collected and preserved in the same temperature as required for ELISA.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in serum GFAP
Time Frame: 1 year
|
GFAP(3) - GFAP (1); GFAP (2) - GFAP (1)
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Valery Subbotin, Ph.D., M.D., Moscow Clinical Scintific Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MKNC 02/2018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.